Bavarian Nordic A/S
BVNRY
Get informed when a big investor buys or sells
+ FollowMarket Cap$17.92B
Close$
Share Statistics
| Market cap | $17.92 Billion |
|---|---|
| Enterprise Value | $17.28 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $5.66 |
| Beta | 0.94 |
| Outstanding Shares | 227,883,789 |
Return
| Return on Equity | 11.79% |
|---|---|
| Return on Assets | 10.58% |
| Return on Invested Capital | 13.90% |
Valuation & Multiples
| P/E Ratio | 12 |
|---|---|
| PEG | 11.4 |
| Price to Sales | 0.45 |
| Price to Book Ratio | 0.2 |
| Enterprise Value to Revenue | 2.84 |
| Enterprise Value to EBIT | 9.07 |
| Enterprise Value to Net Income | 11 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$228.49 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bavarian Nordic A/S
1,906 employees
CEO: Paul John Chaplin Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for sm...